{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:31:54Z","timestamp":1788827514464,"version":"build-2803163510"},"reference-count":71,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union and State of Hungary and co-financed by the European Social Fund","doi-asserted-by":"publisher","award":["TAMOP-4.2.4.A\/2-11\/1-2012-0001"],"award-info":[{"award-number":["TAMOP-4.2.4.A\/2-11\/1-2012-0001"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union and State of Hungary and co-financed by the European Social Fund","doi-asserted-by":"publisher","award":["GINOP-2.3.2-15-2016-00050"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00050"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union and State of Hungary and co-financed by the European Social Fund","doi-asserted-by":"publisher","award":["GINOP-2.3.2-15-2016-00015"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00015"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union and State of Hungary and co-financed by the European Social Fund","doi-asserted-by":"publisher","award":["WI188341"],"award-info":[{"award-number":["WI188341"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["TAMOP-4.2.4.A\/2-11\/1-2012-0001"],"award-info":[{"award-number":["TAMOP-4.2.4.A\/2-11\/1-2012-0001"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["GINOP-2.3.2-15-2016-00050"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00050"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["GINOP-2.3.2-15-2016-00015"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00015"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["WI188341"],"award-info":[{"award-number":["WI188341"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pfizer Investigator Initiated Research","award":["TAMOP-4.2.4.A\/2-11\/1-2012-0001"],"award-info":[{"award-number":["TAMOP-4.2.4.A\/2-11\/1-2012-0001"]}]},{"name":"Pfizer Investigator Initiated Research","award":["GINOP-2.3.2-15-2016-00050"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00050"]}]},{"name":"Pfizer Investigator Initiated Research","award":["GINOP-2.3.2-15-2016-00015"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00015"]}]},{"name":"Pfizer Investigator Initiated Research","award":["WI188341"],"award-info":[{"award-number":["WI188341"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Background: Cardiovascular (CV) morbidity, mortality and metabolic syndrome are associated with rheumatoid arthritis (RA). A recent trial has suggested increased risk of major CV events (MACE) upon the Janus kinase (JAK) inhibitor tofacitinib compared with anti-tumor necrosis factor \u03b1 (TNF-\u03b1) therapy. In our study, we evaluated lipids and other metabolic markers in relation to vascular function and clinical markers in RA patients undergoing one-year tofacitinib therapy. Patients and methods: Thirty RA patients treated with either 5 mg or 10 mg bid tofacitinib were included in a 12-month follow-up study. Various lipids, paraoxonase (PON1), myeloperoxidase (MPO), thrombospondin-1 (TSP-1) and adipokine levels, such as adiponectin, leptin, resistin, adipsin and chemerin were determined. In order to assess flow-mediated vasodilation (FMD), common carotid intima-media thickness (IMT) and arterial pulse-wave velocity (PWV) ultrasonography were performed. Assessments were carried out at baseline, and 6 and 12 months after initiating treatment. Results: One-year tofacitinib therapy significantly increased TC, HDL, LDL, APOA, APOB, leptin, adipsin and TSP-1, while significantly decreasing Lp(a), chemerin, PON1 and MPO levels. TG, lipid indices (TC\/HDL and LDL\/HDL), adiponectin and resistin showed no significant changes. Numerous associations were found between lipids, adipokines, clinical markers and IMT, FMD and PWV (p &lt; 0.05). Regression analysis suggested, among others, association of BMI with CRP and PWV (p &lt; 0.05). Adipokines variably correlated with age, BMI, CRP, CCP, FMD, IMT and PWV, while MPO, PON1 and TSP-1 variably correlated with age, disease duration, BMI, RF and PWV (p &lt; 0.05). Conclusions: JAK inhibition by tofacitinib exerts balanced effects on lipids and other metabolic markers in RA. Various correlations may exist between metabolic, clinical parameters and vascular pathophysiology during tofacitinib treatment. Complex assessment of lipids, metabolic factors together with clinical parameters and vascular pathophysiology may be utilized in clinical practice to determine and monitor the CV status of patients in relation with clinical response to JAK inhibition.<\/jats:p>","DOI":"10.3390\/biom12101483","type":"journal-article","created":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T21:10:10Z","timestamp":1665954610000},"page":"1483","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis"],"prefix":"10.3390","volume":"12","author":[{"given":"Monika","family":"Cz\u00f3kolyov\u00e1","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Hamar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Pusztai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Tajti","sequence":"additional","affiliation":[{"name":"Department of Biophysics and Cell Biology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"V\u00e9gh","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"Peth\u0151","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra","family":"Bodn\u00e1r","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogl\u00e1rka","family":"So\u00f3s","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Szamosi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Szentp\u00e9teri","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"Seres","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-9595","authenticated-orcid":false,"given":"Mariann","family":"Harangi","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Paragh","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Kerekes","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Department of Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levente","family":"Bodoki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Domj\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Hodosi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8623-8217","authenticated-orcid":false,"given":"Tam\u00e1s","family":"Seres","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6227-3301","authenticated-orcid":false,"given":"Gy\u00f6rgy","family":"Panyi","sequence":"additional","affiliation":[{"name":"Department of Biophysics and Cell Biology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-6844","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-9531","authenticated-orcid":false,"given":"Gabriella","family":"Sz\u0171cs","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"ref_1","first-page":"ii67","article-title":"Targeting the Jak\/STAT pathway for immunosuppression","volume":"63","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT signaling in immunity and disease","volume":"194","author":"Villarino","year":"2015","journal-title":"J. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"104609","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.autrev.2010.07.011","article-title":"Biologics-beyond the joints","volume":"9","author":"Szekanecz","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrrheum.2014.121","article-title":"Rheumatoid arthritis and metabolic syndrome","volume":"10","author":"Kerekes","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrrheum.2012.16","article-title":"Validated methods for assessment of subclinical atherosclerosis in rheumatology","volume":"8","author":"Kerekes","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_10","first-page":"398","article-title":"Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: A multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity","volume":"35","author":"Kerekes","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_11","first-page":"710928","article-title":"Metabolic syndrome in rheumatoid arthritis","volume":"2013","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.autrev.2009.02.015","article-title":"Cardiovascular risk in rheumatoid arthritis","volume":"8","author":"Nurmohamed","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"ref_13","first-page":"2425","article-title":"Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis","volume":"33","author":"Dessein","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: Implications for the rheumatologist","volume":"46","author":"Kaplan","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrrheum.2011.107","article-title":"What\u2019s new in our understanding of the role of adipokines in rheumatic diseases?","volume":"7","author":"Gomez","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Choi, H.M., Doss, H.M., and Kim, K.S. (2020). Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041219"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1038\/emm.2013.141","article-title":"The role of adiponectin in the production of IL-6, IL-8, VEGF and MMPs in human endothelial cells and osteoblasts: Implications for arthritic joints","volume":"46","author":"Lee","year":"2014","journal-title":"Exp. Mol. Med."},{"key":"ref_20","first-page":"596","article-title":"High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin","volume":"26","author":"Llorca","year":"2008","journal-title":"Exp. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.yexmp.2011.10.006","article-title":"Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis","volume":"92","author":"Eisinger","year":"2012","journal-title":"Exp. Mol. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3899\/jrheum.140122","article-title":"Circulating concentrations of the novel adipokine chemerin are associated with cardiovascular disease risk in rheumatoid arthritis","volume":"41","author":"Dessein","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_23","first-page":"311","article-title":"Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis","volume":"26","author":"Martin","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1126\/science.2734615","article-title":"Adipsin and complement factor D activity: An immune-related defect in obesity","volume":"244","author":"Rosen","year":"1989","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1042\/CS20200895","article-title":"The complex role of adipokines in obesity, inflammation, and autoimmunity","volume":"135","author":"Taylor","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1002\/art.30449","article-title":"Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis","volume":"63","author":"Knevel","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Czokolyova, M., Pusztai, A., Vegh, E., Horvath, A., Szentpeteri, A., Hamar, A., Szamosi, S., Hodosi, K., Domjan, A., and Szanto, S. (2021). Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-alpha Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology. Biomolecules, 11.","DOI":"10.3390\/biom11101535"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1093\/rheumatology\/kes193","article-title":"Myeloperoxidase and oxidative stress in rheumatoid arthritis","volume":"51","author":"Stamp","year":"2012","journal-title":"Rheumatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2017.05.002","article-title":"Myeloperoxidase: A new player in autoimmunity","volume":"317","author":"Strzepa","year":"2017","journal-title":"Cell Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00296-011-1810-5","article-title":"Increased myeloperoxidase plasma levels in rheumatoid arthritis","volume":"32","author":"Fernandes","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2174\/157016110791112296","article-title":"The axis of thrombospondin-1, transforming growth factor beta and connective tissue growth factor: An emerging therapeutic target in rheumatoid arthritis","volume":"8","author":"Rico","year":"2010","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/clin.1997.4480","article-title":"Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis","volume":"86","author":"Koch","year":"1998","journal-title":"Clin. Immunol. Immunopathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clim.2018.12.011","article-title":"Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis","volume":"199","author":"Balogh","year":"2018","journal-title":"Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00228-004-0820-6","article-title":"Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage","volume":"60","author":"Harangi","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_35","first-page":"214","article-title":"The human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts","volume":"35","author":"Eckerson","year":"1983","journal-title":"Am. J. Hum. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.clinbiochem.2016.03.011","article-title":"Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications","volume":"49","author":"Zsiros","year":"2016","journal-title":"Clin. Biochem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/S0024-3205(03)00195-4","article-title":"Serum paraoxonase activity decreases in rheumatoid arthritis","volume":"72","author":"Tanimoto","year":"2003","journal-title":"Life Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s10067-006-0300-8","article-title":"Paraoxonase and arylesterase levels in rheumatoid arthritis","volume":"26","author":"Isik","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39833","article-title":"Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial","volume":"69","author":"Lee","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/ard.2008.092171","article-title":"Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients","volume":"68","author":"Popa","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-019-04497-0","article-title":"Effects of 1-year anti-TNF-alpha therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis","volume":"40","author":"Vegh","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3899\/jrheum.100668","article-title":"Assessment of subclinical vascular disease associated with ankylosing spondylitis","volume":"38","author":"Bodnar","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3899\/jrheum.090667","article-title":"Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis","volume":"37","author":"Peters","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrrheum.2009.219","article-title":"Vascular effects of biologic agents in RA and spondyloarthropathies","volume":"5","author":"Szekanecz","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: Systematic review and meta-analysis of randomised controlled trials","volume":"78","author":"Xie","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/art.38894","article-title":"Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: A systematic review and meta-analysis","volume":"67","author":"Souto","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1759720X19895492","DOI":"10.1177\/1759720X19895492","article-title":"Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials. Ther","volume":"11","author":"Xie","year":"2019","journal-title":"Adv. Musculoskelet. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Wicker","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e001804","DOI":"10.1136\/rmdopen-2021-001804","article-title":"Prospective, simultaneous assessment of joint and vascular inflammation by PET\/CT in tofacitinib-treated patients with rheumatoid arthritis: Associations with vascular and bone status","volume":"7","author":"Hamar","year":"2021","journal-title":"RMD Open"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00296-017-3844-9","article-title":"Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: A cohort study","volume":"37","author":"Kume","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_53","first-page":"421","article-title":"Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: A metabolomic approach (abstract)","volume":"80","author":"Pusztai","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.20407","article-title":"Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody","volume":"51","author":"Testa","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/art.21707","article-title":"Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis","volume":"55","author":"Llorca","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res Methods"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00198-021-05871-0","article-title":"Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis","volume":"32","author":"Hamar","year":"2021","journal-title":"Osteoporos. Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"A416","DOI":"10.1136\/annrheumdis-2013-eular.1264","article-title":"Effects of tofacitinib on lipid biomarkers in patients with active rheumatoid arthritis (abstract)","volume":"72","author":"McInnes","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12291-010-0097-8","article-title":"Serum paraoxonase levels in patients with acute liver disease","volume":"26","author":"Bindu","year":"2011","journal-title":"Indian J. Clin. Biochem. IJCB"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Brezovec, N., Perdan-Pirkmajer, K., Cucnik, S., Sodin-Semrl, S., Varga, J., and Lakota, K. (2021). Adiponectin Deregulation in Systemic Autoimmune Rheumatic Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084095"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/1756-185X.13724","article-title":"Association of adipokines with rheumatic disease activity indexes and periodontal disease in patients with early rheumatoid arthritis and their first-degree relatives","volume":"22","author":"Castillo","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00296-010-1698-5","article-title":"Synovial\/serum leptin ratio in rheumatoid arthritis: The association with activity and erosion","volume":"32","author":"Olama","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5114\/reum.2022.117839","article-title":"Evaluation of the adipokine profile (adiponectin, resistin, adipsin, vaspin, and leptin) in patients with early rheumatoid arthritis and its correlation with disease activity","volume":"60","author":"Calixto","year":"2022","journal-title":"Reumatologia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/rheumatology\/ken187","article-title":"Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis","volume":"47","author":"Pullerits","year":"2008","journal-title":"Rheumatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/ard.2006.054734","article-title":"Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum","volume":"66","author":"Senolt","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.1038\/s41598-021-87235-6","article-title":"Functional disability is related to serum chemerin levels in rheumatoid arthritis","volume":"11","author":"Celis","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Wahba, A.S., Ibrahim, M.E., Abo-Elmatty, D.M., and Mehanna, E.T. (2021). Association of the Adipokines Chemerin, Apelin, Vaspin and Omentin and Their Functional Genetic Variants with Rheumatoid Arthritis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11100976"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lfs.2014.09.012","article-title":"Increased levels of serum myeloperoxidase in patients with active rheumatoid arthritis","volume":"117","author":"Wang","year":"2014","journal-title":"Life Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3899\/jrheum.141292","article-title":"Upregulation of Thrombospondin 1 Expression in Synovial Tissues and Plasma of Rheumatoid Arthritis: Role of Transforming Growth Factor-beta1 toward Fibroblast-like Synovial Cells","volume":"42","author":"Suzuki","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"El-Banna, H., and Jiman-Fatani, A. (2014). Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis. BMC Musculoskelet. Disord., 15.","DOI":"10.1186\/1471-2474-15-379"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/10\/1483\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:54:25Z","timestamp":1760144065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/10\/1483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":71,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["biom12101483"],"URL":"https:\/\/doi.org\/10.3390\/biom12101483","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}